Skip to main content
Radcliffe Medical Education
Medical education learning resources for healthcare professionals
Radcliffe Medical Education banner
Radcliffe Medical Education banner
  • Home
  •  Davide Capodanno
Davide Capodanno

Davide Capodanno

Professor of Cardiology and Interventional Cardiologist

University of Catania, Catania, IT

Biography

Prof Davide Capodanno is Professor of Cardiology at the University of Catania and Interventional Cardiologist at the Azienda Ospedaliero Universitaria “Policlinico G. Rodolico-S. Marco”, Catania, IT. He is internationally recognised for his expertise in interventional cardiology, thrombosis and cardiovascular clinical research.

With over 500 peer-reviewed publications, five interventional cardiology textbooks and 17 textbook chapters, Prof Capodanno is a prolific author and respected speaker, having delivered more than 200 invited lectures at global cardiology congresses. He is Co-Director of the PCR Clinical Research Course and Associate Director of TCT, two leading platforms for education in cardiovascular interventions.

Prof Capodanno is Editor-in-Chief of EuroIntervention, Associate Editor of the European Heart Journal, Section Editor for Thrombosis and Haemostasis, and Editorial Consultant for JACC: Cardiovascular Interventions. He also serves on the ESC Working Group on Thrombosis and the Educative Solutions Research Group Programme of PCR.

Featured Courses

Revolutionising Thrombosis Treatment in ACS, SSP and AF
  • 1.00 EBAC

Learning objectives

  • Discuss the unmet needs in thrombosis management, MACE burden after ACS, stroke in AF and secondary stroke prevalence and consequences
  • Evaluate the current standard of care for the treatment of ACS, SSP and AF and its limitations
  • Review guidelines and critique current prescribing practices and the implications of inadequate treatment
  • Explain the different strategies for targeting FXI and how FXI inhibition mechanisms differentiate from traditional anticoagulation therapies
  • Identify emerging anticoagulant strategies and describe the efficacy and safety data from Phase 2 FXI inhibitor clinical trials as well as ongoing Phase 3 trials and potential place in therapy for ACS, AF and SSP
  • Apply evidence-based anticoagulation strategies by optimising treatment decisions and addressing patient-specific risk factors
See more